Glutathione S-transferase pi trapping method for generation and characterization of drug-protein adducts in human liver microsomes using liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 67-68, Issue , 2012, Pages 186-192

  Yukinaga, Hideo ^a   Iwabuchi, Haruo ^a   Okazaki, Osamu ^a   Izumi, Takashi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Covalent binding; Human liver microsomes; LC MS; Protein adduct; Reactive metabolite

Indexed keywords

CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE P1; N ACETYL 1,4 BENZOQUINONE IMINE; PARACETAMOL; RALOXIFENE; TRYPSIN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG PROTEIN BINDING; FRACTIONATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIVER MICROSOME; METABOLITE; PRIORITY JOURNAL; PROTEIN TARGETING; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUTATHIONE TRANSFERASE; HUMANS; MICROSOMES, LIVER; MOLECULAR SEQUENCE DATA; TANDEM MASS SPECTROMETRY;

EID: 84862154112     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.04.035     Document Type: Article

References (27)

1. Kalgutkar A.S., Gardner I., Obach R.S., Shaffer C.L., Callegari E., Henne K.R., Mutlib A.E., Dalvie D.K., Lee J.S., Nakai Y., O'Donnell J.P., Boer J., Harriman S.P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 2005, 6:161-225.
2. Zhou S., Chan E., Duan W., Huang M., Chen Y.Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 2005, 37:41-213.
3. Baillie T.A., Davis M.R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 1993, 22:319-325.
4. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baillie T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17:3-16.
5. Park B.K., Boobis A., Clarke S., Goldring C.E., Jones D., Kenna J.G., Lambert C., Laverty H.G., Naisbitt D.J., Nelson S., Nicoll-Griffith D.A., Obach R.S., Routledge P., Smith D.A., Tweedie D.J., Vermeulen N., Williams D.P., Wilson I.D., Baillie T.A. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 2011, 10:292-306.
6. Liebler D.C. Protein damage by reactive electrophiles: targets and consequences. Chem. Res. Toxicol. 2008, 21:117-128.
7. Bateman K.P., Baker J., Wilke M., Lee J., Leriche T., Seto C., Day S., Chauret N., Ouellet M., Nicoll-Griffith D.A. Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem. Res. Toxicol. 2004, 17:1356-1361.
8. Damsten M.C., Commandeur J.N., Fidder A., Hulst A.G., Touw D., Noort D., Vermeulen N.P Liquid chromatography/tandem mass spectrometry detection of covalent binding of acetaminophen to human serum albumin. Drug Metab. Dispos. 2007, 35:1408-1417.
9. Yukinaga H., Takami T., Shioyama S.H., Tozuka Z., Masumoto H., Okazaki O., Sudo K. Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry. Chem. Res. Toxicol. 2007, 20:1373-1378.
10. Obach R.S., Kalgutkar A.S., Soglia J.R., Zhao S.X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 2008, 21:1814-1822.
11. Nakayama S., Atsumi R., Takakusa H., Kobayashi Y., Kurihara A., Nagai Y., Nakai D., Okazaki O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 2009, 37:1970-1977.
12. Jenkins R.E., Kitteringham N.R., Goldring C.E., Dowdall S.M., Hamlett J., Lane C.S., Boerma J.S., Vermeulen N.P., Park B.K. Glutathione-S-transferase pi as a model protein for the characterisation of chemically reactive metabolites. Proteomics 2008, 8:301-315.
13. Boerma J.S., Vermeulen N.P., Commandeur J.N. Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites. Chem. Res. Toxicol. 2011, 24:1263-1274.
14. Qiu Y., Benet L.Z., Burlingame A.L. Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J. Biol. Chem. 1998, 273:17940-17953.
15. Lo Bello M., Parker M.W., Desideri A., Polticelli F., Falconi M., Del Boccio G., Pennelli A., Federici G., Ricci G. Peculiar spectroscopic and kinetic properties of Cys-47 in human placental glutathione transferase. Evidence for an atypical thiolate ion pair near the active site. J. Biol. Chem. 1993, 268:19033-19038.
16. Zheng J., Ma L., Xin B., Olah T., Humphreys W.G., Zhu M. Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry. Chem. Res. Toxicol. 2007, 20:757-766.
17. Yu L., Liu H., Li W., Zhang F., Luckie C., van Breemen R.B., Thatcher G.R., Bolton J.L. Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chem. Res. Toxicol. 2004, 17:879-888.
18. Chen Q., Ngui J.S., Doss G.A., Wang R.W., Cai X., DiNinno F.P., Blizzard T.A., Hammond M.L., Stearns R.A., Evans D.C., Baillie T.A., Tang W. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 2002, 15:907-914.
19. Lohmann W., Hayen H., Karst U. Covalent protein modification by reactive drug metabolites using online electrochemistry/liquid chromatography/mass spectrometry. Anal. Chem. 2008, 80:9714-9719.
20. Baumann A., Karst U. Online electrochemistry/mass spectrometry in drug metabolism studies: principles and applications. Expert Opin. Drug Metab. Toxicol. 2010, 6:715-731.
21. Jurva U., Wikström H.V., Weidolf L., Bruins A.P. Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions. Rapid Commun. Mass Spectrom. 2003, 17:800-810.
22. Damsten M.C., van Vugt-Lussenburg B.M., Zeldenthuis T., de Vlieger J.S., Commandeur J.N., Vermeulen N.P. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem. Biol. Interact. 2008, 171:96-107.
23. Wang J., Davis M., Li F., Azam F., Scatina J., Talaat R. A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem. Res. Toxicol. 2004, 17:1206-1216.
24. Szapacs M.E., Riggins J.N., Zimmerman L.J., Liebler D.C. Covalent adduction of human serum albumin by 4-hydroxy-2-nonenal: kinetic analysis of competing alkylation reactions. Biochemistry 2006, 45:10521-10528.
25. 13C-labeled skin sensitizer 5-chloro-2-methylisothiazol-3-one to human serum albumin: identification of adducts by nuclear magnetic resonance, matrix-assisted laser desorption/ionization mass spectrometry, and nanoelectrospray tandem mass spectrometry. Chem. Res. Toxicol. 2004, 17:1280-1288.
26. Bambal R.B., Hanzlik R.P. Bromobenzene 3,4-oxide alkylates histidine and lysine side chains of rat liver proteins in vivo. Chem. Res. Toxicol. 1995, 8:729-735.
27. Moore C.D., Reilly C.A., Yost G.S. CYP3A4-mediated oxygenation versus dehydrogenation of raloxifene. Biochemistry 2010, 49:4466-4475.